Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

venetoclax 1pirtobrutinib 1nirogacestat 1ibrutinib 1fludarabine phosphate 1cedazuridine 1Watchful Waiting 1Vital Signs 1Tretinoin 1Mycophenolic Acid 1Mesna 1Melphalan 1Lenalidomide 1Immunotherapy, Adoptive 1Filgrastim 1Dexamethasone 1Cyclophosphamide 1Bone Marrow Transplantation 1Azacitidine 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hematologic Diseases × cedazuridine × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡